Recruiting × OTHER × Myeloproliferative Disorders × Clear all Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Phase 2 Recruiting
25 enrolled
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Phase 2 Recruiting
31 enrolled
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Phase 1/2 Recruiting
52 enrolled
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Phase 2 Recruiting
120 enrolled
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Phase 1/2 Recruiting
96 enrolled
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Phase 1/2 Recruiting
27 enrolled
Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021)
Phase NA Recruiting
250 enrolled
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Phase 1 Recruiting
58 enrolled
Evaluation of the Pathobiology of CALR-mutated MPN Cells
Recruiting
35 enrolled
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Phase 1 Recruiting
25 enrolled
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Phase NA Recruiting
400 enrolled
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Phase 1 Recruiting
30 enrolled
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting
30 enrolled
GR-MPN
Phase NA Recruiting
265 enrolled
IT-TCP POS
Phase NA Recruiting
300 enrolled
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Recruiting
5,000 enrolled
AVATARE
Phase NA Recruiting
300 enrolled
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Phase 1 Recruiting
50 enrolled
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Phase 1 Recruiting
15 enrolled
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Phase 1 Recruiting
60 enrolled
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Phase 2 Recruiting
40 enrolled
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
Phase 2 Recruiting
70 enrolled
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 Recruiting
30 enrolled
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Phase 2 Recruiting
100 enrolled
MPN
Phase 1 Recruiting
18 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Phase 2 Recruiting
68 enrolled
Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
Phase 2 Recruiting
56 enrolled
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
Phase 2 Recruiting
29 enrolled
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
Phase NA Recruiting
30 enrolled
Cord Blood Transplant in Adults With Blood Cancers
Phase 2 Recruiting
54 enrolled
EpiC
Recruiting
120 enrolled
PROACTIVE
Phase NA Recruiting
88 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 Recruiting
56 enrolled
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
Phase 2 Recruiting
35 enrolled
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 Recruiting
300 enrolled
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
Phase NA Recruiting
20 enrolled
Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Phase 2 Recruiting
42 enrolled
CLOJAK
Recruiting
120 enrolled
VYP
Recruiting
200 enrolled
Myeloproliferative Neoplasms (MPNs) Patient Registry
Recruiting
5,000 enrolled
SoraGVL
Phase 2 Recruiting
88 enrolled
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
Phase 2 Recruiting
220 enrolled
EMYNEM
Recruiting
10 enrolled
eTHEMA
Recruiting
3,000 enrolled
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Phase 1 Recruiting
24 enrolled
Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.
Recruiting
500 enrolled
Asian Myeloproliferative Neoplasm (MPN) Registry
Recruiting
1,000 enrolled